Othman Laraki is a technology entrepreneur, an investor, and the co-founder and CEO of Color Health. Othman was an early Product leader at Google, where he worked on performance infrastructure and client-side software, including the Google Chrome browser. After leaving Google, he co-founded MixerLabs, which was one of Twitter’s first acquisitions. At Twitter, Othman was the Vice President of Product, helping create the company’s first revenue products and grow the user base from 50 to 200 million users. After leaving Twitter, Othman co-founded Color Health, which he has been leading for the past ten years.

Othman holds degrees in computer science and management from Stanford University and the Massachusetts Institute of Technology. He is a long-time investor and advisor to leading companies such as Pinterest, AngelList, Slack, Instacart, Gitlab, and others.

Caroline Savello is Color’s President, leading the company’s strategy and outcomes in cancer. She has helped build and scale Color’s leadership in the cancer space with employers, labor funds, government institutions, and health plans since joining the organization in 2018. Prior to Color, she worked at Bloomberg LP transforming its global media business and at the Boston Consulting Group, where she focused on global health and life sciences. She is a graduate of Yale University with a joint B.A./M.A. in political science.

Dr. Rebecca Miksad is a mission-driven Physician-Scientist with extensive expertise in cancer and patient-centric health technology and AI solutions. As Chief Medical Officer at Color Health, she oversees Color’s medical and clinical functions, driving the expansion of cancer screening, diagnostics, care navigation, and survivorship tools for program participants.

Dr. Miksad previously founded and led the Strategic Affairs team and Research Unit at Flatiron Health, developing pioneering healthtech products and establishing industry standards for real-world data. Her work has influenced FDA guidances and advanced Health Equity initiatives. With over 100 scientific publications, Dr. Miksad is an internationally recognized leader in oncology, clinical trials and data science. She established the first High Risk Cancer Genetics clinic at Boston Medical Center, where she is an Associate Professor and continues to care for patients. She previously directed the Gastrointestinal Cancer program at Beth Israel Deaconess Medical Center and conducted NIH-funded research. Clinically trained as a medical oncologist,

Dr. Miksad holds an MD with Honors from Cornell University and an MPH in Clinical Effectiveness from Harvard University. For more on her vision on how to impact cancer at scale, read the personally penned article here. Her publications on PubMed can be found here.

Josh Sturm is Color Health’s Chief Revenue Officer. Josh focuses on expanding Color’s partnerships with employers, unions, health plans, and the public sector to provide equitable, accessible healthcare services. An accomplished leader in the healthcare and pharmaceutical sectors, Josh previously was a Vice President at Hinge Health, where he focused on new markets and business development and played a pivotal role in expanding the company’s reach into new territories and complex healthcare ecosystems. Josh’s career includes tenure as a Vice President at Surescripts and at Express Scripts, where he provided strategic oversight and managed significant national accounts. He began his career in sales roles with Allergan and Medicine Shoppe International. Josh earned a B.S. and B.B.A. from Viterbo University and an M.B.A from Webster University.

Stephan Meyer-Ewald is Color’s Chief People Officer. Prior to joining Color, they were the Head of People at Roblox and SmartThings, focusing on helping companies earlier in their lifecycle to navigate through massive growth and frequent changes, while retaining their cultural identity and evolving their leadership practices. They also spent time at Google, where they built out the People Technology and Operations team and led them through a massive scale-up. As a business leader with deep expertise in leadership effectiveness, organization design, and culture building, SME believes building deep, trusting relationships with people across an organization is the key to success. They were born and raised in Nürnberg, Germany, and came to the US 25 years ago, after completing their master’s degree in Computer Science.

Jake Hargraves is Color’s General Counsel and leads all of Color’s legal operations. Prior to joining Color, Jake was an Associate General Counsel at Tesla, where he spent time leading the global employment law team. He also previously served as a Trial Attorney for the U.S. Department of Labor in Washington, DC. Jake began his legal career in his home state of Arkansas, where he worked in private practice and as a prosecuting attorney.

Dany Matar is Color’s Chief Operating Officer. He focuses on delivering Color’s promise of outstanding experience and outcomes to customers and patients. Before joining Color, Dany advised government, healthcare, and life sciences clients as a consultant at McKinsey & Company. He is a physician by training and holds a Masters in Public Health from Johns Hopkins University.

Lee Mallabone is Color’s Senior Vice President of Engineering. He leads the engineering teams that build our digital experiences, platforms and infrastructure. Prior to joining Color, Lee led engineering for several of LinkedIn’s premium subscription businesses and consumer experiences. Earlier in his career, Lee worked as an engineer, an entrepreneur & co-founder. With over 20 years of software development experience and an MEng from the University of York, Lee is passionate about leveraging technology to tackle complex healthcare challenges and improve patient outcomes.

Karthik Rajasekaran, M.D., F.A.S.C. is a distinguished head and neck oncologic and reconstructive surgeon dedicated to providing personalized, patient-centered treatment plans for individuals with benign and malignant tumors. With a commitment to excellence in both clinical care and research, Dr. Rajasekaran is recognized as a leader in the field of head and neck cancer treatment.

Beyond his clinical practice, Dr. Rajasekaran is a prolific researcher with over 175 scientific publications and textbook chapters to his name. His research focuses on improving patient outcomes in advanced head and neck cancer, reducing opioid use in cancer care, and optimizing perioperative management. His contributions have earned him numerous national awards, prestigious research grants, and invitations to present at esteemed national and international conferences.

Dr. Rajasekaran’s unwavering dedication to innovation and patient care continues to shape the future of head and neck cancer treatment, making a lasting impact on the field and the lives of his patients.

Kavita Sarin, M.D./Ph.D., is a Professor of Dermatology and is the Director of the Stanford Skin Cancer Genetics Program at the Stanford Cancer Institute. She has an academic interest in Precision Medicine, focused on the integration of genetic and clinical patient data to inform susceptibility, prognosis, and treatments in skin cancer and other rare dermatologic disorders. Her lab applies cutting-edge sequencing and imaging technologies to better understand skin cancer and rare immunologic skin diseases. She sees patients in medical dermatology at Portola Valley and the Stanford Cancer Institute.

Lidia Schapira, M.D. is a medical oncologist with clinical expertise in the treatment of breast cancer. She is the Inaugural Director of Stanford's Cancer Survivorship Program and a professor of medicine at Stanford University School of Medicine. Dr. Schapira has developed a thriving research and clinical program focused on optimizing health outcomes for people living with and beyond cancer. Her clinical research focuses on improving cancer care and outcomes with a particular focus on young adults with breast cancer and cancer survivors.

Dr. Schapira received her medical degree from the Geisel School of Medicine at Dartmouth University. She completed her residency in internal medicine at the Beth Israel Deaconess Hospital in Boston and fellowships at the Brigham and Women’s Hospital and Harvard Medical School.

Dr. Schapira is leading efforts to build capacity for caring for the growing number of cancer survivors by designing and championing training for healthcare professionals and resources for patients and family caregivers. She has published numerous manuscripts and lectures, both nationally and internationally, on issues of cancer survivorship.

Dr. Jill Kruse is a family physician and CEO of Flight Time Medical. She is also hospitalist at Brookings Health System. She earned her DO degree at Des Moines University- College of Osteopathic Medicine and Surgery. Her residency training was at the University of Wisconsin Madison-Baraboo Rural Training Track.

At Flight Time Medical, she serves as a Senior Aviation Medical Examiner for the FAA and enjoys flying her Grumman Tiger airplane in her free time.

Dr. Kruse is one of the hosts of the television show “On Call with the Prairie Doc” on South Dakota Public TV. She has done significant work in physician wellness as one of the founders and first medical director of the Avera LIGHT program. She wrote two chapters in “Transforming the Heart of Practice: An Organizational and Personal Approach to Physician Wellbeing”.

She has also received the American Medical Association Women’s Section “Inspirational Physician Award” and the Catholic Health Association’s “Tomorrows Leader Award”. Along with her fellow Prairie Docs, she received the South Dakota State Medical Association‘s “Richard Holm Media Award” and the “Community Service Award”.

Dr. Liz Etkin-Kramer is a board-certified gynecologist who has been in clinical practice in South Florida since the 1990s. She serves as an Assistant Professor of Obstetrics and Gynecology at the FIU Herbert Wertheim College of Medicine and holds multiple leadership roles within District XII of the American College of Obstetricians and Gynecologists (ACOG).

Dr EK is a huge proponent of personalized risk assessment for women's health. Through her work with ACOG District XII’s Patient Safety and Quality Improvement (PSQI) committee, Dr. EK has created educational material for both the gynecologist and their patients on breast cancer risk assessment and management. She educates other health care providers on breast and ovarian cancer risk assessment and management, inclusive of genetic testing for hereditary cancer.

In 2018, Dr.EK founded Yodeah.org, a nonprofit organization committed to increasing awareness within the Ashkenazi Jewish community about hereditary cancer risk and providing access to affordable genetic testing. To date, she has counseled and tested thousands of men and women regarding their cancer risks based on the results of genetic testing.

Allison Kurian, M.D., M.Sc. is a Professor of Medicine and of Epidemiology and Population Health at Stanford University. She is Associate Chief of the Division of Oncology, Director of the Stanford Women’s Clinical Cancer Genetics Program, Co-Leader of the Population Sciences Program and Co-Director of the Data Science Core for the Stanford Cancer Institute. Dr. Kurian graduated from Stanford University, attended Harvard Medical School followed by Internal Medicine residency at Massachusetts General Hospital, and completed Medical Oncology fellowship and a master’s degree in Epidemiology at Stanford University.

Dr. Kurian’s research focuses on the identification of women with elevated breast and gynecologic cancer risk, and on the development and evaluation of novel techniques for early cancer detection and risk reduction. As an oncologist and epidemiologist, she aims to understand cancer burden and improve cancer treatment quality at the population level. Her research employs methods from the population sciences, in collaboration with the Surveillance Epidemiology and End Results (SEER) Program and other large, real-world data resources. Dr. Kurian leads epidemiologic studies of cancer risk factors, clinical trials of novel approaches to cancer risk reduction, and decision analyses of strategies to improve cancer outcomes. She has published more than 320 peer-reviewed articles, and her research has been supported by grants from the National Institutes of Health, California Breast Cancer Research Program, Komen for the Cure Foundation, Breast Cancer Research Foundation, and others. Dr. Kurian’s work has been honored by Impact Awards of the National Consortium of Breast Centers and the BRCA Foundation, selection as a Komen Scholar and election to the American Society of Clinical Investigation.

Mary-Claire King, Ph.D. grew up in Chicago. She received her BA cum laude in Mathematics from Carleton College in Minnesota, her PhD in Genetics from the University of California at Berkeley, and her postdoctoral training at UC San Francisco. She was professor at UC Berkeley from 1976-1995 and has been American Cancer Society Professor of Medical Genetics and of Genome Sciences at UW since 1995.